0.00Open1.20Pre Close0 Volume31 Open Interest0.50Strike Price0.00Turnover658.81%IV20.57%PremiumAug 16, 2024Expiry Date0.91Intrinsic Value100Multiplier23DDays to Expiry0.29Extrinsic Value100Contract SizeAmericanOptions Type0.9275Delta0.0587Gamma1.28Leverage Ratio-0.0071Theta0.0001Rho1.19Eff Leverage0.0005Vega
Nektar Therapeutics Stock Discussion
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
No comment yet